CITY THERAPEUTICS, INC.
No SEC Form 4 filings for $CTY in the last 30 days.
See all $CTY insider activity →City Therapeutics (NASDAQ:CTY) priced its IPO at $18 per share, offering 11.11M shares for ~$200M. Underwriters have a 30-day option for additional shares. Trading begins on Nasdaq under CTY. The company focuses on RNA interference therapeutics.
City Therapeutics, a biotech developing RNAi drugs, filed for an IPO seeking up to $184.7M, offering 9.7M shares at $17-$19 each. The company plans to list on Nasdaq under CTY. Its lead candidate, CITY-FXI, showed promising Phase 1 trial results. The company has raised $238.8M in equity and reported a $53.4M net loss for H1 2026. Proceeds will fund clinical development and research. (350 characters)
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CTY (CITY THERAPEUTICS, INC.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
IPO pricing and first-day listing mechanics should drive near-term liquidity and sentiment, with focus on deal size, float, and clinical-stage risk.
The IPO filing provides fresh capital for clinical development, likely generating buying interest while also introducing dilution.
AlphAI scores every news story that mentions CTY with an AI model for sentiment and relevance, and aggregates insider trades from CITY THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
City Therapeutics (NASDAQ:CTY) priced its IPO at $18 per share, offering 11.11M shares for ~$200M. Underwriters have a 30-day option for additional shares. Trading begins on Nasdaq under CTY. The company focuses on RNA interference therapeutics.
3 min readCity Therapeutics, a biotech developing RNAi drugs, filed for an IPO seeking up to $184.7M, offering 9.7M shares at $17-$19 each. The company plans to list on Nasdaq under CTY. Its lead candidate, CITY-FXI, showed promising Phase 1 trial results. The company has raised $238.8M in equity and reported a $53.4M net loss for H1 2026. Proceeds will fund clinical development and research. (350 characters)
2 min read
